Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
Earlier BMS lacked microcontrollers, advanced sensors, and data-processing capabilities, meaning they couldn't monitor each cell in detail, estimate State of Charge (SoC) or State of Health (SoH), or ...
Bristol Myers Squibb (BMS) has agreed as part of a deal with the US government to provide Eliquis (apixaban) free of charge to Medicaid. The company has also agreed to donate more than seven tons of ...
The future of electric vehicles depends on battery packs that are safe, efficient, and easy to maintain. Wireless battery-management systems introduce a new way to cover all of these needs. What’s the ...
Nearly 4,500 Tesla Model 3 and Model Y owners in South Korea have complained about battery malfunctions that prevent charging. The problem, which primarily affects 2021 models, has drawn the scrutiny ...
Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...
BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with ...
Beecher Manufacturing Services acquired BMS Manufacturing Co. in Watkins Glen, New York. The acquisition will help Ward Apparatus, another Beecher company, increase fire truck production. The ...
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...
Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...
On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is serving up mixed results for the first three months of the year. Still, even as ...
While it is common to hear that drug developers are in the early stages of integrating artificial intelligence with their drug research, discovery, and development efforts, one Bristol Myers Squibb ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results